Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","amount":"$8.2 million","upfrontCash":"$8.2 million","newsHeadline":"Fresh Tracks Announces $8.25 Million Buyout of its Right to Receive Future Sofpironium Bromide Payments from Botanix","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Botanix Pharma

    Menu

    Botanix Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Botanix Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Fresh Tracks Announces $8.25 Million Buyout of its Right to Receive Future Sofpironium Bromide Payments from Botanix

              Details:

              Under the agreement, Fresh Tracks provided consulting services as an independent contractor to Botanix in support of and through filing and approval of the U.S. new drug application for BBI-4000 (sofpironium bromide gel).

              Lead Product(s): Sofpironium Bromide

              Therapeutic Area: Dermatology Product Name: BBI-4000

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Fresh Tracks Therapeutics

              Deal Size: $8.2 million Upfront Cash: $8.2 million

              Deal Type: Agreement July 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY